<DOC>
	<DOCNO>NCT02944110</DOCNO>
	<brief_summary>Patients diabetes characterise compromised insulin secretion action , also elevate plasma level 29-amino acid peptide hormone glucagon , hitherto consider pancreas-derived hormone ( produce secrete alpha cell islet Langerhans ) . In patient diabetes , circulate glucagon concentration elevate fast state fail decrease appropriately even increase response oral glucose tolerance test ( OGTT ) ingestion mixed meal . Hyperglucagonaemia known potent stimulator hepatic glucose output , , thus , contribute significantly fast postprandial hyperglycaemia characterise patient diabetes . Despite intense research year mechanisms behind elevate glucagon level diabetes still clear . Recently , investigator show totally pancreatectomised patient also show hyperglucagonaemic response OGTT , find suggests pancreas source glucagon production man . In present project , investigator wish evaluate impact gastrointestinally derive glucagon secretion observe totally pancreatectomised patient postprandial glucose tolerance . The investigator hypothesise antagonisation glucagon signalling ( gastrointestinally derive glucagon ) totally pancreatectomised patient improve perhaps normalise patient glucose tolerance 75g-OGTT . In order test hypothesis , investigator wish apply potent selective oral antagonist human glucagon receptor LY2409021 placebo , respectively . The study randomise , placebo-controlled , double-blinded , cross-over study . 10 healthy person 10 pancreatectomized patient ( i.e . patient pancreata remove due pancreatic cancer severe chronic pancreatitis ) subject two experimental day LY2409021 placebo , respectively , undergo OGTT follow fasting period finish ad libitum meal .</brief_summary>
	<brief_title>Delineation Diabetogenic Role Extrapancreatic Glucagon Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism</brief_title>
	<detailed_description />
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Inclusion criterion Pancreatectomised patient Caucasian 18 year age undergone total pancreatectomy Normal haemoglobin Informed consent Healthy subject Normal fast plasma glucose normal HbA1C ( accord World Health Organization ( WHO ) criterion ) Normal haemoglobin Age 18 year Informed consent Exclusion criterion Pancreatectomised patient Inflammatory bowel disease Operation within last 3 month Ongoing chemotherapy chemotherapy within last 3 month Gastrointestinal resection ( gastroduodenectomy perform connection total pancreatectomy ) and/or ostomy Nephropathy ( serum creatinine &gt; 150 µmol/l and/or albuminuria ) Severe liver disease ( serum alanine aminotransferase ( ALAT ) and/or serum aspartate aminotransferase ( ASAT ) &gt; 3× normal value ) Pregnancy and/or breastfeed Age 80 year Uncontrolled hypertension and/or significant cardiovascular disease Any condition investigator feel would interfere trial participation Healthy subject Diabetes prediabetes ( accord WHO criterion ) Firstdegree relative diabetes Inflammatory bowel disease Gastrointestinal resection and/or ostomy Nephropathy ( serum creatinine &gt; 150 µM and/or albuminuria Liver disease ( ALAT and/or serum ASAT &gt; 2×normal value ) Pregnancy and/or breastfeed Age 80 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>